Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
November 20, 2018
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
June 25, 2018
Publication date:
October 25, 2018
Applicant:
NOVALIQ GMBH
Inventors:
Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
February 8, 2017
Date of Patent:
August 28, 2018
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
March 16, 2011
Date of Patent:
August 14, 2018
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
April 4, 2018
Publication date:
August 9, 2018
Applicant:
NOVALIQ GMBH
Inventors:
Bastian THEISINGER, Sonja THEISINGER, Bernhard GüNTHER
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
July 24, 2017
Date of Patent:
May 15, 2018
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
September 21, 2017
Publication date:
March 15, 2018
Applicant:
NOVALIQ GMBH
Inventors:
Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
Type:
Application
Filed:
September 29, 2017
Publication date:
January 25, 2018
Applicant:
NOVALIQ GMBH
Inventors:
Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
July 24, 2017
Publication date:
January 11, 2018
Applicant:
NOVALIQ GMBH
Inventors:
Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
September 26, 2017
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Günther, Dieter Scherer, Anthony Pettigrew
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
October 18, 2011
Date of Patent:
September 12, 2017
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
September 12, 2017
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
Abstract: The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.
Type:
Application
Filed:
April 19, 2017
Publication date:
August 3, 2017
Applicant:
NOVALIQ GMBH
Inventors:
Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
Abstract: The invention provides semi-solid or liquid pharmaceutical compositions for topical administration to a finger- or toenail of a human. The compositions are useful for the delivery of active ingredients deep into the nail. Various active ingredients may be incorporated, such as antifungal agents, anti-infectives, anti-inflammatory agents, immunosuppressants, local anesthetics, and retinoids.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
April 12, 2016
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Gunther, Bastian Theisinger, Sonja Theisinger
Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
Type:
Application
Filed:
September 12, 2013
Publication date:
August 13, 2015
Applicant:
Novaliq GmbH
Inventors:
Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.
Abstract: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.